Aligos Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALGS Nasdaq 2836 www.aligos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aligos Therapeutics, Inc.

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - Sep 2nd, 2026 6:00 am
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates - Sep 2nd, 2026 4:45 am
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Aug 12th, 2026 2:05 pm
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Aug 6th, 2026 6:00 am
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 - Jul 30th, 2026 6:00 am
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection - Jul 13th, 2026 6:00 am
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Jul 6th, 2026 5:50 pm
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Jul 6th, 2026 2:05 pm
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - May 13th, 2026 12:05 am
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - May 7th, 2026 2:05 pm
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - Apr 30th, 2026 2:05 pm
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 24th, 2026 6:00 am
Aligos and Xiamen Amoytop sign deal for HBV therapy - Apr 17th, 2026 4:54 am
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Apr 16th, 2026 4:00 am
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation - Apr 14th, 2026 2:05 pm
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - Mar 5th, 2026 6:00 am